Biocon Biologics secures multiple market access agreements for Yesintek
Express Scripts has added YESINTEK to the National Preferred Formulary (NPF) effective March 21, 2025. Cigna has added YESINTEK to its commercial formulary beginning on March 21, 2025. UnitedHealthcare has added YESINTEK to several formularies including commercial beginning May 1, 2025; managed Medicaid beginning March 1, 2025; and Medicare beginning June 1, 2025. CVS Health has added YESINTEK beginning July 1, 2025. And finally, Optum Rx has added YESINTEK to its Premium and Select formularies beginning July 1, 2025.
YESINTEK has also been selected on several other formularies, including Navitus, Costco Health Solutions, MedImpact, Priority Health, University of Pittsburgh Medical Center (UPMC), and several other regional health plans. Additionally, YESINTEK has been selected as the exclusive Ustekinumab by Blue Cross Blue Shield of Michigan (BCBSM), Florida Healthcare Plan, and several closed-door health systems.
The Company is also finalizing formulary agreements with other commercial carriers.
YESINTEK is approved for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, increasing patient access to more cost-effective treatment options for use in the treatment of common chronic autoimmune diseases. YESINTEK is available in all the same formulations currently provided by STELERA . The available presentations are 45 mg/0.5 mL PFS, 90 mg/mL PFS, 45 mg/0.5 mL vial, and 130 mg/26 mL vial.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
a day ago
- Mint
Centene Earnings Fall Short of Expectations as Woes Mount
(Bloomberg) -- Centene Corp. reported a surprise quarterly loss Friday, yet another disappointment for the embattled health insurer, which recently pulled its 2025 guidance citing revenue pressure. Shares dropped 11% before markets opened in New York. They had fallen 56% since the start of the year. Centene said it would provide updated guidance on a conference call with analysts, which starts at 8 a.m. New York time. The insurer chalked up the second-quarter loss to a miscalculation in its Affordable Care Act business — the same reason it pulled guidance earlier this year. Insurers receive compensation for taking on sicker patients in that program and Centene said it would receive less of that money than it had previously expected. For the second quarter, Centene announced an adjusted loss per share of 16 cents. Wall Street analysts expected a profit of 55 cents per share. 'We are disappointed by our second quarter results, but we have a clear understanding of the trends that have impacted our performance, and are working with urgency and focus to restore our earnings trajectory,' Sarah London, chief executive officer of Centene, said in the company's earnings statement. In the second quarter, the company spent 93% of premium revenues of medical costs, higher than the average analyst expectation of 91.6%. Investors prefer a lower number. The company said its health benefits ratio, the percentage of premium revenues spent on medical costs, rose from last year, largely because of the ACA revenue issue. Centene said it also saw higher medical costs in ACA plans, as well as increased costs in Medicaid, which mostly came from behavioral health, home health, and expensive drugs. --With assistance from John Tozzi. (Updates with new information throughout.) More stories like this are available on
Time of India
2 days ago
- Time of India
Pressures build: Donald Trump's tariffs, Big Beautiful Bill may play party pooper for India's IT sector; here's how
AI image India's top IT firms are witnessing weak demand across key verticals such as manufacturing, consumer, communications and life sciences, which together account for 40–70% of revenues for several large players, as clients cut discretionary spending and defer projects amid global economic and policy headwinds. According to analysts, these sectors—once seen as growth engines diversifying revenue away from BFSI (banking, financial services and insurance)—are now reeling under tariff-related supply chain disruptions and the impact of America's 'Big Beautiful Bill' (BBB), which has led to a rollback of clean energy incentives and regulatory shifts in healthcare, according to an ET report. Tata Consultancy Services (TCS) flagged pressures in the MedTech segment, citing heightened regulatory scrutiny, changing demand patterns, cost concerns, regional consolidation and elevated customer expectations. 'The pharmaceutical sector, which is witnessing pricing, supply chain challenges and export risk, is prioritising R&D, profit margin and operational efficiency,' InCred Equities said in a report. 'Leading companies in the US, UK, Europe and Japan are consolidating vendors while leveraging AI.' The healthcare bill recently passed in the US includes nearly $1 trillion in cuts to Medicaid over 10 years, rollbacks to the Affordable Care Act, and a $500 billion reduction in Medicare spending. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like No annual fees for life UnionBank Credit Card Apply Now Undo 'This could severely impact the earnings of Medicaid-focused insurers and hospitals,' InCred warned. Tech Mahindra, which earns nearly 70% of its revenues from these stressed verticals, lost a major hi-tech deal and is now pivoting toward BFSI and retail to drive future growth, the firm noted. BFSI and retail show resilience Amid the turmoil, BFSI and retail have emerged as more stable revenue drivers. Infosys reported that its financial services vertical continues to perform strongly, driven by vendor consolidation and digital transformation deals. Though it registered growth in manufacturing and auto during the last quarter, the company remains cautious about the outlook. Similarly, HCL Technologies has not seen a worsening in discretionary spending in financial services and technology. In its post-results note, Motilal Oswal said the company is optimistic about sustaining growth in BFSI. 'The first half of 2025 presented a mixed bag for IT services companies, characterised by macroeconomic uncertainties, global trade policy shifts, and evolving client spending priorities,' said Nitin Bhatt, Technology Sector Leader, EY India. He noted that the BBB's aggressive tariffs and rollback of green subsidies have weighed on manufacturing and automotive firms—especially those focusing on EVs and sustainable technologies—leading to increased input costs and delayed IT investments as companies shift focus to cost optimization. While the pharmaceutical industry has generally been more resilient, Bhatt said it too is now showing signs of softness. Stay informed with the latest business news, updates on bank holidays and public holidays . AI Masterclass for Students. Upskill Young Ones Today!– Join Now
Time of India
2 days ago
- Time of India
US tariffs, big beautiful bill derail Indian IT's big shift away from BFSI
ETtech India's IT earnings are being dragged down by verticals such as manufacturing, consumer, communications and life sciences, which together constitute 40-70% revenues for several large by tariff-led supply chain disruption and America's Big Beautiful Bill, these sectors – which have been instrumental in diversification from banking, financial services and insurance - are now witnessing project postponements and cuts in discretionary instance, Tata Consultancy Services (TCS) noted that the MedTech industry is witnessing regulatory scrutiny, demand changes, cost pressure, regional consolidation, new business models and higher customer expectations.'The pharmaceutical sector, which is witnessing pricing, supply chain challenges and export risk, is prioritizing R&D, profit margin and operational efficiency,' stock research firm InCred Equities said in a report. 'Leading companies in the US, UK, Europe and Japan are consolidating vendors while leveraging AI.'The recent passage of the healthcare bill includes nearly $1 trillion cuts to Medicaid funding over 10 years, rollback to the Affordable Care Act, and $500 billion in Medicare spending reduction. This could severely impact the earnings of Medicaid-focused insurers and hospitals, InCred noted. TechMahindra , which derives 70% of its revenues from these stressed verticals and lost a major deal in hi-tech, is now shifting gears towards BFSI and retail, which will be its future growth drivers, it core BFSI and retail verticals have continued to show resilience and are emerging as more stable growth engines, data showed. Infosys noted the financial services is emerging as its strongest verticals due to vendor consolidation and transformation deals. Although Infosys emerged as an outlier with strong positive growth in manufacturing and auto during the bygone quarter, there is continued cautiousness in these sectors, it HCL Technologies , discretionary spending in financial services and technology has not worsened as earlier anticipated, Motilal Oswal noted in its post results analysis. The company is confident of maintaining growth momentum in BFSI, it said.'The first half of 2025 presented a mixed bag for IT services companies, characterized by macroeconomic uncertainties, global trade policy shifts, and evolving client spending priorities,' said Nitin Bhatt, Technology Sector Leader, EY instance, manufacturing and auto verticals have been significantly affected. 'The "Big Beautiful Bill" (BBB) in the US, with its aggressive tariffs and energy policy shifts, has created uncertainty. The rollback of clean energy incentives impacts manufacturing and auto companies focused on EVs and sustainable technologies. This has resulted in delays or reductions in IT investments, as companies prioritize cost optimisation amid supply chain disruptions and increased input costs from tariffs,' Bhatt added that the pharma sector, which generally tends to be more resilient, has also experienced some forward, businesses are expected to adapt to the new normal which could bring back spending, albeit at a lower growth rate as previously anticipated.
